About the PK Lab
- The Center for Drug Design (CDD) Pharmacokinetics (PK) lab aims to facilitate medicinal chemists' efforts to discover new lead candidates with proper drug-like properties, and to obtain research funding and publish academic research findings.
- The PK lab is supported by the CDD and was initially established to provide ADME/PK support within the center. In the last five years, the lab has studied the preclinical ADME/PK of more than 300 compounds from various CDD drug discovery projects, and has contributed to the application of two awarded R01 NIH grants and the publication of 16 joint manuscripts.
- The PK lab is equipped with a state-of-the-art LC-MS instrument (Agilent 1260 HPLC and AB Sciex QTrap 5500 MS) that is used to detect and quantitate small molecules in biological matrices.
- The PK lab also manages an Agilent 6230B Time of Flight LC/MS system with capability of high resolution mass.
- The PK lab has licensed Phoenix WinNonlin software for PK data analysis and modeling.
LC/MS/MS bioanalytical services
- Express LC/MS/MS method development
- Advanced LC/MS/MS bioanalysis method development and validation according to FDA guidelines
- Quantitative analysis of small molecules and peptides from biological samples (including plasma and other organs from in vivo bio-distribution studies), or food and environmental samples
In vitro ADME
- Microsomal stability, Plasma stability, S9 stability, Aqueous stability
- Cytochrome P450 inhibition, Cytochrome P450 reaction phenotyping
- Plasma protein binding, Brain tissue binding, Blood to plasma ratio
- Caco-2, MDCK and PAMPA permeability
- Oral bioavailability of drugs in mice and rats
- PK Data analysis with non-compartmental or compartmental models